Basic Review of the Autophagy Machinery
While three types of autophagy—macroautophagy, microautophagy, and chaperon-mediated
autophagy (CMA)—have been described,[1]
[2] this review only discusses macroautophagy and its role in the liver. To simplify
the description, the term “autophagy” will be used throughout the text to refer to
“macroautophagy” ([Table 1]).
Table 1
Major concepts and learning points
|
Term
|
Concept
|
Learning points
|
|
Autophagy
|
An evolutionarily conserved process for delivering intracellular materials for degradation
in the lysosome
|
1. Three types of autophagy: macroautophagy, microautophagy, chaperon-mediated autophagy,
which differ in the way by which cellular materials are delivered to the lysosome.
|
|
2. Virtually all cellular constituents could be delivered in a bulk or selective way.
|
|
3. Its activity is regulated by multiple environmental and internal cues in response
to different needs and stress.
|
|
4. In macroautophagy, multiple molecules, designated as ATG molecules, are involved
in the core process of autophagosome biogenesis, cargo recognition, and delivery to
the lysosome.
|
|
DAMP and HMGB1
|
Damage-associated molecular patterns (DAMPs), also known as danger-associated molecular
patterns, danger signals, or alarmin, refer to a heterogenous group of biological
substances that triggers sterile inflammation in response to stress or following cell
death.
|
1. High-mobility group box 1 (HMGB1) is one of the best characterized DAMPs. This
protein normally binds to DNA with uncharacterized function. But it translocates to
the external space either due to cell breakdown or by an active mechanism that involves
inflammasomes. Its effect can be mediated by one of the following receptors that are
present on different types of cells: RAGE, TLR2, or TLR4.
|
|
2. HMGB1 has diverse functions, not only in promoting inflammation or fibrosis but
also in promoting repair/regeneration, such as angiogenesis and proliferation. It
has also been linked to the regulation of tumorigenesis, autophagy, and other processes.
Its function can thus be context-dependent.
|
|
3. Other DMAP members can include heat shock proteins, adenosine triphosphate, uric
acids, DNA, etc.
|
|
Ductular Reaction and hepatic progenitor cells
|
Ductular reaction is the histology manifestation of the expansion of ductular cells,
also known as hepatic progenitor cells, in the hepatic parenchyma. Ductular reaction
is frequently present in chronic liver diseases.
|
1. The significance of ductular reaction is still not well understood. Some consider
it as a regenerative/repair process, whereas others consider it to be associated with
poor prognosis and severe cirrhosis.
|
|
2. The origin of ductular cells is not well defined. They may be derived from cholangiocytes
and/or hepatocytes, as they carry markers from both types of cells. Ductular cells
may give rise to regenerating hepatocytes or cholangiocytes, and hence they are also
known as hepatic progenitor cells.
|
|
3. The mechanism of their expansion and contraction is not defined well. Certain proteins
have been found to have growth factor-like activity.
|
The basic autophagy machinery operates to maintain a basal level of autophagy activity
in cells, which is required for the constitutive turnover of cytosolic components,
that is, the cargos. The activity of this machinery is enhanced or reduced in response
to the changing environment and the cellular needs.[6] Signaling events lead to the modulation of autophagy machinery at the transcriptional
or translational level, which then drives the change in activity.[7]
The three types of autophagy differ mainly in the way the cargos are transported to
the lysosome. In macroautophagy, the cargos are delivered to the lysosome by the double-membraned
vesicle, known as the autophagosome. At the cellular level, the macroautophagy process
begins with the formation of a double-membraned cup-shaped structure, called phagophore,
whose edges extend and sequester cytosolic components to sequester them in the growing
autophagosomal vesicles.[8] Formation of the autophagosomes are the morphological signature of autophagy induction.
Autophagosomes then fuse with lysosomes to deliver and break down its contents.[9] The source of the phagophore membrane has not been completely resolved but may include
the endoplasmic reticulum (ER), the Golgi apparatus, the mitochondria, the endocytic
membrane, or the plasma membrane.[10]
At the molecular level, autophagy is driven by a concerted action of a suite of ATG,
or “autophagy-related” molecules. The number of these ATG molecules varies in different
species, but the core members are evolutionarily conserved.[11] The majority of autophagy molecules have been shown to function as complexes to
drive the autophagy process. Seven functional groups or complexes have been described
in the mammalian cells to perform the key steps in autophagosome formation.[11]
-
ULK1 tetrameric kinase complex: This is also called initiator complex and is composed
of ULK1, FIP200, Atg13L, and Atg101.
-
Beclin1 complex: The basic components are Beclin1, VPS34 (also known as phosphatidylinositol
3-kinase [PI3K] catalytic subunit 3), and VPS15 (also known as PI3K regulatory subunit
4), which are joined by Atg14 to form complex I, or by UVRAG to form complex II. Beclin1
also interact with several autophagy regulatory molecules, including NRBF2, Ambra-1,
RUBICON, and Bcl-2 with either inhibitory or stimulating effects.
-
Phosphatidylinositol 3-phosphate (PtdIns3P) binding complex: It includes proteins
such as Zinc finger FYVE domain-containing protein 1 (DFCP1) and WD-repeat domain
phosphoinositide-interacting proteins (WIPI) 1/2/3/4 that are recruited to PI3P. These
proteins bind to PI3P through its FYVE domains and promote the formation of the omegasome.
-
Ubiquitin-like conjugation system I: This includes an ubiquitin-like molecule, Atg5,
and its conjugating partner Atg12, which then forms a supramolecular complex with
Atg16L1.
-
Ubiquitin-like conjugation system II: This includes another ubiquitin-like molecule,
LC3B, or other Atg8 homologues. They are conjugated to phosphatidylethanolamine (PE).
-
E1-like and E2-like enzymes: They include the E1-like molecule Atg7, and the E2-like
molecule, Atg10 (for Atg5-Atg12 conjugation), or Atg3 (for LC3B-PE conjugation).
-
Atg9A: This is a multimembrane spanning Atg protein postulated to serve as a membrane
carrier for phagophore extension.
The initiation of phagophore begins with the activation of ULK1 kinase complex and
the formation of ULK1 punctae at a discrete location on the ER. Activated ULK protein
complex recruits and activates the Beclin1 complex to the phagophore through phosphorylation.
Beclin1-/Atg14-directed activation of the VPS34/VPS15 kinase generates a local pool
of PtdIns3P. This alteration in the lipid composition changes the membrane curvature,
further expansion of phagophore and local recruitment of the oligomers of Atg5-Atg12-Atg16L.
The latter facilitates LC3B conjugation to PE on the autophagosomal membrane. LC3B
lipidation causes further expansion and enclosure of the autophagosomal membrane.
Formation of autophagosomes may be followed by a maturation process in the mammalian
cells through fusion with other endocytic membranes. The amphisome, product of the
maturation process, eventually fuses with the lysosome for cargo degradation.
For the precise and efficient fusion of the double-membraned autophagosomes with the
single-membraned lysosome, tethering factors (HOPS complex, RAB7, and adaptors) and
fusion machinery SNARE proteins are involved.[1] Lysosomal hydrolases degrade the inner autophagosomal membrane and expose the autophagosomal
cargo for further degradation. The degradation products, including amino acids, sugar,
and free fatty acids (FFAs) are transported out of the autolysosome via the lysosomal
permeases/efflux transporters. During the termination step of autophagy, lysosome
is regenerated by a process called autophagic lysosome reformation (ALR). ALR involves
autolysosome tubulation, scission and budding, and generation of the protolysosomes,
which is matured to become the lysosomes.[12]
[13]
Interestingly, autophagosomes are generally formed in the peripheral region of the
cells whereas lysosomes are clustered around perinuclear regions during cellular stress
such as starvation.[14] To achieve efficient fusion of autophagosomes and lysosomes, autophagosomes are
transported along microtubules (dynein mediated) toward perinuclear region where lysosome
are located.[14]
Besides bulk cargo degradation, autophagy can selectively transport a given type of
cargos for degradation. The selectivity of the autophagy process seems to be governed by the organelle that give rise to
the membrane. The molecule/s that confers exclusivity during the selective progress is not clear. Depending on the particular type of cargo
involved, autophagy may be named as mitophagy (damaged mitochondria), proteophagy
(protein aggregates), pexophagy (peroxisomes), lipophagy (lipid droplets), ferritinophagy
(ferritin), ribophagy (ribosomes), or xenophagy (intracellular microorganisms).[15]
[16] Selective cargo degradation relies on a plethora of selective autophagy receptors
or adaptors such as p62/SQSTM1, NBR1 (neighbor of BRCA1 gene 1), NDP52 (nuclear domain
10 protein 52kDa), and OPTN (optineurin). They generally bind to the cargo (often
ubiquitinated) and key components of the autophagy machinery, especially the LC3 protein
to mediate the selective engulfment of the cargo by the autophagosome.[15]
[17]
Role of Autophagy in Metabolic Homeostasis
In the light of the liver's function in the metabolic control of the body, it is not
surprising that autophagy is an integrated part of the mechanism. Hepatic autophagy
is important for the maintenance of systemic nutrient and energy balance. The catabolic
role of autophagy can be responsible for the breakdown of glycogen, lipids, and proteins
in response to the needs of the body.
Degradation of Macromolecules for Nutrient Needs
Hepatic autophagy contributes significantly to the maintenance of the blood glucose.
While in adults hepatic glycogen is mainly mobilized through the action of the phosphorylase
and debranching enzymes in the cytosol, it is almost exclusively hydrolyzed by lysosomal
acid glucosidase in the neonatal stage.[18] Immediately after birth or following the treatment of glucagon, the number and size
of autophagic vacuoles containing glycogen are increased.[19] In newborn hepatocytes, autophagic vacuoles are distributed predominantly at the
border of hyaloplasmic glycogen stores. They mostly contain engulfed glycogen at various
states of disintegration. Interestingly, liver glycogen in the newborn hepatocytes
(fetal-type glycogen) differs from that in adult cells, for example, in the degree
of branching. Other than glycogen degradation, autophagy also degrades proteins to
generate amino acids for hepatic gluconeogenesis,[20] which can also contribute to glucose homeostasis.
Protein degradation maintains the intracellular amino acid pool and the plasma level
of amino acids. Other than meeting metabolic needs, autophagic degradation of protein
may also contribute to protein quality control by removing misfolded and aggregated
proteins, alleviating proteotoxicity caused by an abnormal level of proteins. Degradation
of a particular protein may have a particular impact. Degradation of hexokinase 2
(HK2) can directly affect liver glycolysis.[21] Degradation of p62/SQSTM1, an adaptor/receptor of selective autophagy, is not only
a part of the normal autophagy process, but also is key to prevent abnormal activation
of Nrf2, which can otherwise cause significant liver pathology.
Breakdown of triglycerides (TGs) by lipophagy may provide the needed energy during
nutrient deprivation. In hepatocytes, newly formed TGs are stored as cytoplasmic lipid
droplets (LDs). Mobilization of neutral lipids from LDs generates FFAs for mitochondrial
oxidation and energy production. TGs in LDs could be enzymatically hydrolyzed to FFA
either by cytosolic lipolysis (known as neutral lipolysis, via adipose TG lipase i.e.,
ATGL) or by lipophagy (known as acidic lipolysis via lysosomal acid lipase [LAL]).[22] The functional coordination of the two lipolysis pathways is not well studied. Surprisingly,
ATGL is recently shown to be both necessary and sufficient to drive autophagy/lipophagy
in the liver in response to starvation.[23] Promotion of ATGL-mediated LD turnover and FFA oxidation was completely abrogated
when autophagy was pharmacologically or genetically blunted. Mechanistically, ATGL
promotes SIRT1 activation to activate hepatic autophagy.[23] These studies indicate that the two lipolysis pathways in the hepatocyte are well
connected and coordinated in a much closer way than we have expected.
Regulation of Autophagy during the Switch of Fast-Fed State
Liver metabolism dynamically alters between anabolism and catabolism depending on
the nutrient status. As a catabolic process, hepatic autophagy occurs at low rates
under fed condition (constitutive or basal autophagy), but it is strongly induced
under fasting or starvation conditions (induced autophagy). Multiple signaling events
can occur to regulate the autophagy activity.
Cells integrate the up-stream signals (such as these mediated by the AMPK and/or mTORC1
pathway) and the transcriptional regulation to maintain appropriate control of autophagy.
Many transcriptional regulators have been known to regulate autophagy in mammalian
cells, including p53, STAT3, NF-κB, FoxO1/3, SIRT1, TFEB, HIF1α, GATA, and ATF4.[24] Notably, FXR and PPARα are two nutrient sensing nuclear receptors that modulate
autophagy at the transcriptional level in close association with the liver metabolism.[25]
[26]
In the fasting condition, glucagon is activated and acts on hepatocytes to raise the
level of cAMP. The subsequent activation of the cAMP/PKA signaling pathway leads to
(1) inactivation of FXR to allow PPARα to access to the PPARα promoters of several
lysosomal and autophagy genes; (2) phosphorylates Ser133 of CREB to promote its nuclear translocation; and (3) inhibition of salt-inducible
kinases (SIKs), which phosphorylate Ser171 of CREB-regulated transcription coactivator 2 (CRTC2) to retain it in the cytoplasm.
These events lead to the formation of CREB/CRCT2 complex and their nuclear translocation.
Once in the nucleus, CREB/CRCT2 (1) upregulates the expression of genes of the gluconeogenesis
pathway; (2) upregulates expression of TFEB, which in turn promotes autophagy and
lysosomal biogenesis genes; (3) increases PPARα and its co-activator PGC1α expression
to elevate the expression of genes involved in autophagy, lysosome biogenesis, and
β-oxidation; and (4) increase LAL gene to increase lysosomal lipid degradation.
In parallel, lower levels of hepatocellular nutrients, particularly amino acids, cause
downregulation of mTORC1 activity, leading to de-phosphorylation of cytosolic pool
of TFEB and S6 kinases 2 (S6K2). Both of these events cause increased nuclear translocation
of TFEB and cytosolic export of a transcriptional repressor, NCoR1, leading to increased
expression of autophagy and lysosome biogenesis genes.
Conversely, in the fed condition, elevations of amino acids, glucose, and fatty acids,
together with an abundant level of insulin, promote mTORC1 activation at lysosomal
surface, leading to (1) phosphorylation of TFEB to prevent its nuclear translocation,
which will induce expression of several autophagy and lysosome-related genes, and
(2) phosphorylation of ribosomal protein S6K2. Phosphorylated S6K2 forms complex with
NCoR1 and then translocate to the nucleus to repress the expression of catabolic genes,
such as β-oxidation pathway genes.[25]
[26]
In parallel, fed-state sensing nuclear receptor FXR (1) binds to CREB and disrupts
the functional complex between CREB and CRTC2; (2) competes with another nutrient-sensing
regulator, PPARα, for binding on the promoter sites, known as the DR1 element, which
presents in many autophagy genes, and inhibits their expression. All these molecular
events assure the prevention of autophagy activation. However, basal autophagy level
is maintained during this process.
Role of Autophagy in Fasting-Induced Hepatic Steatosis
One of the interesting features during fasting is the development of hepatic steatosis.
FFAs generated by lipolysis in adipose tissue enter hepatocytes and are temporarily
stored in the form of LDs before they are oxidized by the hepatic mitochondria, or
secreted as VLDL. Surprisingly, autophagy-deficient hepatocytes fail to mount fasting-induced
steatosis.[27]
[28]
[29] Thus, autophagy is critical for starvation-induced LD formation in liver cells.
It is thought that LC3-II binding to LDs is essential for the LD enlargement in hepatocytes.[29] The mechanism of impaired fasting-induced LD biogenesis in autophagy-deficient livers
is unknown. It seems that this failure is not related to any adaptive changes in de
novo lipogenesis, β-oxidation, or VLDL secretion, but it is related to Nrf2 activation
since co-deletion of Nrf2 in autophagy-deficient livers restored the adaptive steatosis.[30] This dual dole of hepatic autophagy in lipophagy versus LD biogenesis and its impact
in hepatic lipid metabolism is an enigmatic issue that requires further studies.
The Homeostatic Role of Autophagy: Consequences of Autophagy Deficiency
Autophagy dysfunction due to external (improper diet or chemicals) or internal (molecular
defects) factors can render hepatocytes vulnerable to a variety of stress, resulting
in severe liver pathogenesis. Notably, genetically inherited pathogenic mutations
in any of the reported autophagy genes are rarely reported in humans. A study identified
a homozygous missense mutation in Atg5 that caused mental retardation, developmental
delays, and congenital ataxia.[31] The same mutation in the yeast and the fly caused reduced autophagy and movement
disorder, respectively. But no liver presentation was reported. Constitutive deletion
of key autophagy genes in mice causes perinatal lethality,[32] which may explain the lack of loss-of-function mutation in human. Tissue-specific
deletion of autophagy genes allows the characterization of important function of autophagy
in specific organs and the pathology resulted from the lack of such function ([Table 2])
Table 2
Systemic and conditional Atg gene knock out mouse, and associated phenotype
|
Type
|
Genotype
|
Tissue
|
Gene Function
|
Phenotype
|
Citation(s)
|
|
Conventional
|
Atg3 −/−
|
Whole body/systemic
|
Phosphatidylethanolamine (PE) conjugation enzyme to Atg8 like E2
|
Death immediately after birth, suckling defect
|
[83]
|
|
Atg5 −/−
|
Whole body
|
E3 like activity for Atg8 conjugation system in corporation with Atg12
|
Death immediately after birth, suckling defect
|
[32]
|
|
Atg7 −/−
|
Whole body
|
Atg8- or Atg12-activating enzyme like E1
|
Death immediately after birth, suckling defect
|
[28]
|
|
Atg9 −/−
|
Whole body
|
The only membrane protein among Atg genes
|
Death immediately after birth, suckling defect
|
[84]
|
|
Atg12 −/−
|
Whole body
|
Ubiquitin-like protein covalently attached to Atg5
|
Death on postnatal day 1
|
[85]
|
|
Atg13 −/−
|
Whole body
|
ULK1 protein complex, Autophagy initiation step
|
Death in utero, growth retardation of embryos and myocardial growth defect
|
[86]
|
|
Atg16L −/−
|
Whole body
|
Interact with Atg12-Atg5 complex
|
Death immediately after birth, suckling defect
|
[58]
|
|
Beclin 1 −/−
|
Whole body
|
Bcl-2 binding protein and a component of PI3 kinase complexes
|
Developmental defect and death in utero (E7.5d-E8.5d)
|
[72]
[73]
|
|
FIP200 −/−
|
Whole body
|
Protein kinase
|
Embryonic death at mid/late gestation associated with heart failure and liver degeneration
|
[87]
|
|
Conditional
|
Alb-Cre-Vps34 −/−
|
Hepatocyte, Cholangiocyte
|
Class III phosphoinositide 3-Kinase (PI3K)
|
Hepatomegaly, steatosis, increased fatality
|
[88]
|
|
Conditional
|
Alb-Cre-Atg7 −/−
|
Hepatocyte, Cholangiocyte
|
Atg8- or Atg12-activating enzyme like E1
|
Hepatomegaly, liver injury, inflammation, fibrosis, hepatoma
|
[34]
[38]
|
|
Conditional
Inducible
|
Atg7 F/F Mx1-Cre
|
Hepatocyte
|
Atg8- or Atg12-activating enzyme like E1
|
Hepatomegaly, liver injury, inflammation, fibrosis, hepatoma
|
[28]
|
|
Conditional
Inducible
|
Atg5 F/F Mx1-Cre
|
Hepatocyte
|
E3-like activity for Atg8 conjugation system in corporation with Atg12
|
Hepatomegaly, liver injury, inflammation, fibrosis, hepatoma
|
[89]
|
|
Conditional
Inducible
|
Ert-Atg7F/F
|
Hepatocyte
|
Atg8- or Atg12-activating enzyme like E1
|
Hepatomegaly, liver injury, inflammation, fibrosis, hepatoma
|
[38]
[90]
|
|
Conditional
|
ULK1/2 −/−
|
Hepatocyte, Cholangiocyte
|
Autophagy initiation
|
Hepatomegaly
|
[91]
|
|
Conditional
|
FIP200 −/−
|
Hepatocyte, Cholangiocyte
|
Autophagy initiation
|
Hepatomegaly, liver injury, inflammation, and hepatic fibrosis
|
[27]
|
|
Conditional
|
Atg7 F/F GFAP-Cre
|
Stellate cell
|
Atg8- or Atg12-activating enzyme like E1
|
Normal liver architecture and intact stellate cell ultrastructure, no liver injury,
attenuated liver fibrosis following liver injury
|
[39]
|
|
Conditional
|
Atg5 F/F Lzy2-Cre
|
Macrophage
|
E3-like activity for Atg8 conjugation system in corporation with Atg12
|
Polarization of macrophage into proinflammatory M1 type
|
[40]
|
Regarding the liver, autophagy genes have been deleted in parenchymal cells, stellate
cells, or Kupffer cells, leading to different phenotypes ([Table 2]). It has to be pointed out that autophagy-deficient mice created by crossing mice
with a floxed autophagy gene to the Albumin-Cre transgenic mice will have deletion
of the floxed autophagy gene not only in hepatocytes but also in cholangiocytes, since
the albumin promoter starts working at E15 in embryonic hepatoblasts, which give rise
to both hepatocytes and cholangiocytes. Thus these mice have autophagy deficiency
in parenchymal cells (Atg
ΔPar
). By crossing the same floxed mice to transgenic mice expressing a modified tamoxifen-inducible
Alb-Cre promoter (Alb-CreERT2), one can induce the deletion of the floxed autophagy gene in adult mice so that
the impact can be limited to the hepatocytes, since the albumin promoter only works
in hepatocytes in adult livers (Atg
ΔHep-ERT2
). While several autophagy genes have been deleted in the parenchymal cells ([Table 2]), Atg7
ΔPar
and Atg5
ΔPar
mice were best characterized,[28]
[33]
[34]
[35]
[36]
[37]
[38] which have a most complicated pathologic presentation, including hepatomegaly, injury,
inflammation, ductular reaction (DR), fibrosis, and tumorigenesis.[28]
[33]
[37]
[38] This phenotype has been largely replicated in the Atg7
ΔHep-ERT2
mice,[38] suggesting that autophagy deficiency in the hepatocytes is the main driving force
for the alterations.
Loss of autophagy in stellate cells reduces fibrotic response in injury as autophagy
is required for the maturation of these cells.[39] The phenotype in mice bearing Atg5 deletion in the myeloid compartment is not restricted
to the liver but the autophagy-deficient macrophages had abnormalities in polarization,
which enhanced hepatic inflammatory response and liver injury in fatty liver disease
models.[40]
Interestingly, the liver phenotypes caused by autophagy deficiency in parenchymal
cells resemble those seen in clinically common chronic liver diseases caused by other
etiologies, such as hepatitis virus, alcohol, or high fat diet. Thus, it is possible
that these pathologies share similar or common molecular mechanisms although unique
signaling components may be required to trigger these pathological changes in response
to specific etiologies. Thus, the study of the pathology in autophagy-deficient liver
can provide important mechanistic insights to the similar process in other chronic
liver diseases.
p62/SQSTM1 and Nrf2 Key Cellular Players
The specific signaling leading to the common pathological changes in autophagy-deficient
livers is not well understood. Although the direct effect of autophagy deficiency
is the failure to degrade certain cargos, not all cargos would have pathologic significances
if accumulated. Abnormal mitochondria accumulated due to autophagy deficiency are
often considered to be pathogenic because they can be the major source of ROS.[41]
[42] However, the real culprit may actually be something else, which amplifies the dire
consequence of autophagy deficiency.
It has been found that nuclear factor (erythroid-derived 2)-like 2, also known as
Nrf2, is persistently activated in autophagy-deficient hepatocytes due to the accumulation
of p62/SQSTM1.[35] p62/SQSTM1 is a major cargo of autophagy, and its amount is massively elevated in
autophagy deficiency.[28]
[33]
[41] p62/SQSTM1 binds to Keap1 (Kelch-like ECH-associated protein 1), weakening the interaction
of Keap1 with its target protein, Nrf2, which allows Nrf2 to escape from the ubiquitination
by a E3-lighase complex recruited by Keap1 and degradation by the proteasome.[35] Undegraded Nrf2 translocates from the cytosol to the nucleus and activates a whole
series of transcriptional targets.
Genetic deletion of Nrf2 in Atg7
ΔPar
or Atg5
ΔPar
mice largely suppressed autophagy deficiency-induced liver pathologies.[33]
[35]
[38] Consistently, genetic deletion of p62 in autophagy-deficient liver also alleviated most of the liver pathophysiology.[34]
[41] It is not entirely clear how persistent activation of Nrf2 could lead to all the
major pathological changes. We have evidence that controlling hepatic high-mobility
group box 1 (HMGB1) release is one of the mechanisms (see later). It is possible that
some of the genes under the transcriptional regulation of Nrf2 are responsible for
the pathological outcomes. Paradoxically, Nrf2 is known to activate a variety of antioxidant
genes (HO-1, Nqo1, Gstm, etc.) and hepatic detoxification enzymes under normal conditions
in response to oxidative stress.[43] Indeed, these genes were highly overexpressed in autophagy-deficient livers. It
is possible that the Nrf2 toxicity in this context is mediated by other Nrf2's targets.
The almost complete suppression of the liver pathologies by Nrf2 deletion raises another important issue. Atg7
ΔPar
or Atg5
ΔPar
mice with Nrf2 deletion appear normal morphologically and in function. However, these
hepatocytes do not regain the macroautophagic function enabled by Atg7 or Atg5. It
is possible that this deficiency is well compensated by the noncanonical Atg7-/Atg5-independent
pathway,[44] or by the CMA.[45] An argument against this possibility is that these compensatory mechanisms, if effective,
do not seem to be potent enough to prevent or alleviate Nrf2-mediated pathology in
the Atg7- or Atg5-deficient hepatocytes. An alternative but radical hypothesis is that Atg7-/Atg5-mediated
macroautophagic degradation may not be as important for hepatocyte function as expected.
These considerations are important but are yet to be examined further experimentally.
Injury in Mice with Autophagy Deficiency in the Liver
Liver injury, as measured by elevated blood AST, ALT, and ALP levels, is a prominent
feature in Atg7
ΔPar
or Atg5
ΔPar
livers. However, several puzzling observations can be made. One is that liver injury
is more significant in Atg7
ΔPar
livers than in Atg5-deficient livers[38] (Bilon Khambu and Xiao-Ming Yin, unpublished observations, 2018). In fact, liver
injury is alleviated in older Atg5
ΔPar
mice.[33] The reason for this difference is not clear but may be related to the fact that
Atg7 lies at the upstream of Atg5 in the conjugation system, although deletion of
either gene results in completely defective LC3 conjugation and accumulation of p62/SQSTM1
to the similar level.[28]
[33]
[38]
The other interesting observation is that the extent of protection against liver injury
by the deletion of p62/SQSTM1 in Atg7
ΔPar
mice is not as robust as that of the deletion of Nrf2,[34]
[35] suggesting that there might be unidentified factor/s other than p62/SQSTM involved
in the persistent Nrf2 activation. In addition, while Nrf2 deletion in Atg7
ΔPar
mice rescues most of the injury phenotypes, the level of ALP remains high[35 ](Bilon Khambu and Xiao-Ming Yin, unpublished observations, 2018), suggesting that
there are Nrf2-independent pathological events. Finally, despite the robust liver
injury observed, cell death does not seem to be widely spread in the liver and caspase
activation seemed to be minor.[33]
[38]
Overall, these observations recapitulate the question on the mechanism of liver injury
in Atg
ΔPar
mice, or the question on how persistent activation of Nrf2 can cause liver injury.
Toward that, there could be several possible hypotheses. They are not mutually exclusive
and in fact could be well overlapped, resulting in the actual scenarios.
Quantitative Proteotoxicity
Misfolded proteins can be toxic to cells, a phenomenon known as proteotoxicity. In
the autophagy-deficient cells, both correctly folded and misfolded proteins are dramatically
increased due to inhibition of the degradation of normal long-lived protein and abnormal
aggregated proteins by autophagy. In addition, persistent Nrf2 activation leads to
overproduction of many of its target molecules. Proteomic analysis of autophagy-deficient
liver shows increases in total protein mass, and there are no specific changes in
the protein composition in these livers.[46] An excess amount of proteins, even correctly folded, could be toxic to cells, which
is thus provisionally termed as quantitative proteotoxicity. This toxic effect may
be manifested as hepatocyte hypertrophy, hepatomegaly, and liver injury. Treating
mice with a generic protein synthesis inhibitor, cycloheximide, reduced liver injury
to some degree (Bilon Khambu and Xiao-Ming Yin, unpublished observations, 2018), which
could support the proteotoxicity hypothesis.
Hepatic Lobular Structure Alterations and Cholestatic Injury
These hypertrophied hepatocytes may alter the hepatic lobular structure, sinusoid
deformation, hepatocyte detachment from the matrix, cholestasis, or hemostasis. All
of these may lead to liver injury. We have observed deformation of bile canaliculi
and elevation of blood bile acid level (Bilon Khambu and Xiao-Ming Yin, unpublished
observations, 2018), which in combination of extensive DR in the autophagy-deficient
livers (see later) may indicate cholestatic injury.
Intrinsic Molecular Defects
The deficiency of autophagy in the hepatocytes and/or the persistent activation of
Nrf2 causes intrinsic cellular defect as the molecular pathways have been altered.
These alterations result in defective physiological process and hence cell injury.
Extrinsic Cause of Hepatocyte Injury
In this hypothesis, cellular injury is not caused by the intrinsic cell-autonomous
failure but rather due to secondary events, the recruitment and activation of immune
cells, which are responsible for the inflammation and cellular injury in the AtgΔPar livers.[28]
[33]
[38]
Role of HMGB1 in Hepatic Pathogenesis Caused by Autophagy Deficiency
Autophagy deficiency leads to inflammation, fibrosis, DR, which represents the expansion
of hepatic progenitor cells (HPCs) or ductular cells (DCs), and tumorigenesis. These
presentations resemble those observed in many common chronic liver diseases caused
by other etiologies, such as virus, alcohol, or high fat. However, the mechanisms
are complicated and there might be individual signaling pathways initiated by specific
etiology and common pathways that are accountable for the common features.
Two recent studies[38]
[47] indicate that one of the damage-associated molecular pattern molecules, HMGB1, can
serve as a signaling mechanism to two of these changes, the DR and tumorigenesis,
one in the context of autophagy deficiency,[38] and the other in the autophagy-competent condition,[47] again indicating common mechanism can be present in chronic liver injury caused
by different etiologies.
Mechanism of HMGB1 Release
HMGB1 is a nuclear protein but its role in the nucleus is not very clear.[48] Acetylation of HMGB1 can lead to the translocation from the nucleus to the cytosol,
which can be a pathological response.[49] Release of HMGB1 to the extracellular space is often due to cellular breakdown as
the result of cell death. However, active secretion of HMGB1 from live macrophages
is known to be mediated by the inflammasome.[50]
[51]
Inflammasomes are multimeric protein complexes formed to produce inflammatory cytokines,
IL-1β and IL-18. There are several inflammasomes, which are activated in response
to different pathogen-associated molecular patterns. Activation of all types of inflammasome
leads to the recruitment and activation of Caspase-1. Activated Caspase 1 proteolytically
processes IL-1β and IL-18, as well as a pore-forming protein Gasdermin D (GSDMD),
which is responsible for the release of the two cytokines.[52]
[53]
[54] Notably, besides Caspase-1, Caspase-11 can also recognize and cleave GSDMD.[53]
[54]
Externalization of HMGB1 by hepatocytes under a variety of pathological conditions
have been described.[38]
[47]
[55]
[56] While in most cases this release seems to be caused by cellular breakdown, it is
by active secretion via the inflammasome in autophagy-deficient hepatocytes.[38] In earlier studies, the link of autophagy and inflammasome had been observed in
macrophages for the secretion of IL-1β.[57] Association of inflammasome activities with certain autophagy genes, such as ATG16L,
LC3B, and Beclin1, has been observed in other mammalian cells.[58]
[59] In the liver, activation of the inflammasome has been reported in not only nonparenchymal
cells, but also in parenchymal cells under other cases.[60]
[61] However, the molecular mechanisms had not been mapped out in these cases. In the
case of autophagy-deficient hepatocytes, we now find that Nrf2 is required for the
activation of Caspase-1, and that both Nrf2 and Caspase-1 are required for HMGB1 release
independent of cellular injury.[38] In fact, Nrf2 activation alone in the absence of autophagy deficiency is sufficient
to trigger HMGB1 release in an inflammasome-dependent manner. This study thus provides
a molecular example of how inflammasomes in hepatocytes may be activated.
Role of HMGB1 in Ductular Reaction
The function of HMGB1 is quite diverse and is likely context-dependent.[48]
[62] It is known as a danger-associated molecular pattern (DAMP) and is in general associated
with sterile inflammation, fibrosis, and angiogenesis among other functions. However,
when HMGB1 was deleted in the autophagy-deficient livers, neither inflammation nor
fibrosis was noticeably affected,[38] indicating that these two processes were mainly mediated by other molecular pathways
that have yet to be defined. Surprisingly, HMGB1 plays important roles in two other
pathological presentations in autophagy-deficient livers, DR, and tumor development.[38]
Ductular reaction is commonly seen in liver diseases with chronic injury[63] and represents the expansion of DCs, also known as oval cells in rat and HPCs in
some literatures.[63]
[64] Morphologically, DCs are small cells with a high nuclear/cytosol ratio. Their origin
is controversial and may represent different populations depending on the nature of
injury. Both biliary epithelial cells and hepatocytes have been postulated to give
rise to DCs, as DCs seem to be mainly originated from the portal-parenchymal interface.
They express several biliary cell markers, such as CK19, Sox9, and EpCAM, and hepatocyte
markers, such as CK18 and albumin.[63]
[64]
The driving force for the expansion of DCs is still far from clear. In autophagy-deficient
livers, HMGB1 seems to be a major driving force. It possesses a mitogenic effect in
vitro on DCs. Genetic deletion of HMGB1 or pharmacological inhibition of HMGB1 release
results in long-term suppression of DR.[38] Notably, in several other mouse models of liver injury, including that caused by
the genetic deletion of Mdr2, by the DDC diet, the choline-deficient, ethionine-supplemented diet, or by diethylnitrosamine
(DEN) treatment, HMGB1 was important for the expansion of DCs.[38]
[47] RAGE (receptor for advanced glycation endproducts) is an HMGB1 receptor, which is
also required for DR in autophagy-deficient livers,[38] as well as for DR in Mdr2-deficient livers,[65] DDC-treated livers,[38]
[47] and DEN-treated livers,[47] whereas other HMGB1 receptors, such as TLR4, TLR9 did not seem to be involved.[47] These studies indicate that the HMGB1-RAGE signaling axis could be generally important
for the expansion of DCs.
Several other factors have been indicated in the DR, including FGF7, TNF-related WEAK
inducer of apoptosis (TWEAK) and TWEAK receptor Fn14,[66]
[67] connective tissue growth factor, integrin αVβ6, and ADAMTS7.[64] The relationship of these signaling pathways with that of HMGB1-RAGE would be important
to be delineated.
The functional relevance of DR in liver diseases is not entirely understood. It is
widely believed that DCs act as “facultative” progenitor cells that could give rise
to either cholangiocytes or hepatocytes, depending on which compartment is injured.
Thus DR seems to represent a repair/regeneration response. Liver injury is elevated
in autophagy-deficient livers when HMGB1 is deleted,[38] which could be related to a poor DR and thus a poor repair process.
Role of HMGB1 in Tumorigenesis
Autophagy-deficient liver develops spontaneous tumor that steadily increased in size
and number as the mice get older.[37]
[38]
[68]
[69] In Atg7-deficient liver, tumors start to appear beginning from 9 months of age,
which increases steadily through 15 to 17 months. As discussed in the following section,
there could be several molecular events involved in the tumorigenesis in autophagy-deficient
livers. Interestingly, HMGB1 and its receptor RAGE are also important in promoting
tumor development.[38]
No tumors were grossly observable in the liver of HMGB1-codeleted or RAGE-codeleted
autophagy-deficient livers at the age of 9 months. The tumors were developed in these
mice at a later time point of 15 to 17 months. However, the size and number of tumor
were still not as significant as in the presence of HMGB1.[38] We still do not understand how HMGB1-RAGE may affect tumor development in this context,
but it does not seem to be related to some of the early tumorigenic events, such as
metabolic reprogramming or hedgehog signaling.[38]
It is intriguing that HMGB1 regulates both DR and tumorigenesis as DCs has been considered
by some studies to be a cellular compartment susceptible to malignant transformation.[70] However, in several models of murine hepatic tumors, direct evidence that DCs gave
rise to HCC had not been found.[71] Thus, the connection of the two pathological processes regulated by HMGB1 and how
HMGB1 promotes tumor development have yet to be determined.
Role of Autophagy in Hepatic Tumorigenesis
Autophagy is important for the maintenance for hepatocellular homeostasis and its
dysfunction can lead to hepatic tumors. In general, autophagy maintains the homeostasis
of normal cells and thus suppresses tumorigenesis. However, autophagy is also used
in tumor cells as an alternative mechanism for nutrients supply and elimination of
damaged organelles. It can thus function as a pro-tumor mechanism. In the liver context,
most of the studies based on autophagy deficiency suggest the antitumorigenic role
of autophagy.
The first genetic evidence showing disruption of autophagy executing genes may be
an important mechanism of hepatic tumorigenesis was based on observation of tumor
lesions in haplo-sufficient Beclin1-deficient mice.[72]
[73] Loss of autophagy genes Atg7
[68] or mosaic Atg5-deletion[37] in rodent liver also lead to hepatic tumors in aged mice. Besides the observations
in the mouse models, association of autophagy deficiency with the development of HCC
has been reported in human cases.[74] In human HCC tissues, decreased Atg5 or Beclin1 gene expression together with p62 accumulation (low autophagic activity) were observed
in comparison with that in adjacent non-tumor tissues.[75] Selective recruitment and autophagic degradation of oncogenic miR-224 or cell cycle
regulator Cyclin D were reported to affect liver tumorigenesis.[76] This may indicate that autophagy can have a more direct impact on tumorigenesis.
The Role of Mitochondria Damage and ROS
One potential mechanism could be aberrant signaling regulated to hepatocellular mitochondrial
dysfunction and ROS production. Studies in Atg7- or Atg5-deficient models have established that autophagy-deficient hepatocytes have mitochondrial
dysfunction, oxidative stress, and DNA damage, which are key contributing factors
for tumor development.[33]
[37]
[42] All these factorial changes in autophagy-deficient hepatocytes may culminates in
hepatocellular adenoma.[33]
[37]
[42] Liver-specific Atg5-deficient mice fed with an oxidant N-acetylcysteine had a reduced level of oxidative
stress in the liver and reduced liver tumor incidence.[42]
The Role of Nrf2
Abnormal accumulation of p62/SQSTM1 could lead to dysregulated activation of NF-κB
pathway,[77]
[78] Wnt signaling,[79] or Nrf2 activation.[35] Simultaneous deletion of Nrf2 in mice with hepatic deficiency in Atg7 or Atg5 strikingly
reduced the size and numbers of tumors.[33]
[35]
[38] Notably, hyperactivation of Nrf2 associated with p62 accumulation has been observed
in certain types of human HCC.[36]
[68]
In addition to its classical role of Nrf2 in redox homeostasis, Nrf2 has a new role
in metabolic reprogramming.[36]
[80] In autophagy-deficient livers, phosphorylation of p62 at Ser351 activates Nrf2 to
elevate the expression of Nrf2 target genes, which include those encoding enzymes
involved in the pentose phosphate pathway and glutamine metabolism.[81] Thus, Nrf2 redirects glucose metabolism to the glucoronate pathway, directs glutamate
toward glutathione synthesis, and hence supports cell proliferation in addition to
enhancing cytoprotection.[36] This dual role of Nrf2 between redox and metabolic regulation seems to provide the
survival benefits to the tumorigenic hepatocytes. Finally, as mentioned earlier, Nrf2
can also control the release of HMGB1, which promotes tumor development in autophagy-deficient
livers (see earlier).
Invasive Hepatocellular Carcinoma vs. Noninvasive Hepatic Adenoma
Hepatic tumors in autophagy-deficient livers seem to be well-capsulated noninvasive
hepatoma by morphology. Interestingly, treatment of a well-defined carcinogen diethyl
nitrosamine (DEN) caused invasive HCC in wild type livers, but not in autophagy-deficient
livers.[42] The tumor suppressor genes p53 seems to play an important role in arresting the development of a more malignant
phenotype. The levels of p53 and several other tumor-suppressor genes, such as p21,
p16, and Rb1, are increased in liver adenoma tissues of Atg5-deficient livers.[42] In the absence of mitophagy, p53 is phosphorylated by PINK1 at Srine-392, and is
translocated into the nucleus to suppress the expression of NANOG,[82] which could be important for the development of cancer stem cells. It is thought
that the activation of CSC is important for the emergence of the malignant invasive
HCC, which could be lacking in autophagy-deficient livers due to p53 activation.